JAK1 and plasma cell myeloma: Further, the expression of JAK1 and JAK2 were previously reported to be upregulated in some MM cells and the JAK1/JAK2 inhibitor Ruxolitinib in combination with Bortezomib, Itacitinib or Daratumumab inhibited JAK/STAT3 phosphorylation, inhibited in vitro and in vivo myeloma cell growth and induced cell apoptosis [94-96].